Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
about
Antibody responses to envelope glycoproteins in HIV-1 infectionHIV-1 neutralizing antibodies: understanding nature's pathwaysAntibodies in HIV-1 vaccine development and therapyHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionVirological features associated with the development of broadly neutralizing antibodies to HIV-1Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1Co-evolution of a broadly neutralizing HIV-1 antibody and founder virusBroad and potent neutralization of HIV-1 by a gp41-specific human antibodyHeavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding SitesNeutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorCross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env GeneHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodiesB-cell-lineage immunogen design in vaccine development with HIV-1 as a case studyPlasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesBroad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trialsNeutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccinesThe potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development.Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypesBone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individualsCharacterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.Strategies to guide the antibody affinity maturation processThe Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single InfectionBroadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortBroadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and SubclassesBroad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.The development of CD4 binding site antibodies during HIV-1 infection.
P2860
Q26991572-648A92B2-7EE2-4F75-A96A-27BE31BC9743Q27000480-C4357CA4-D8A6-4877-B4AA-8FFAB49649A9Q27011574-91C678AE-CCDC-44D9-9FCB-9DDBF09A5CD6Q27022055-01BCF835-047F-4C21-B017-BF4F8CA1A577Q27022652-8C9CCCAD-3F6F-48E8-998C-899CC856D888Q27025177-9392CB4B-3BE2-4384-8C6A-AB0D7EE6D4CAQ27322403-9C9F73A8-051F-4F65-A2AF-421B9B614B68Q27644501-4FFB2E99-A612-458F-BE90-E45BC8BAFDB0Q27675131-BEE654F5-21F8-43DE-82F8-EEF52677C554Q27679031-F4D9CCB0-8E2A-4602-BE7B-DA90B61EC365Q27684529-D84E5842-7415-457E-8C33-2C786B106397Q28554907-258323FE-E6C5-4A5D-80B2-C09FA77C2586Q28602877-10EAA73F-C3A3-4EC6-95F8-8A3637D0395EQ30234773-CAB5DC07-9C77-43BE-90C4-241F3DF0EE5EQ33594304-6BC4F73F-AEB0-45D4-8FFC-90D09E57D623Q33702217-C606E506-E70A-4539-9DB7-1B0F256A6D30Q33804531-7A2A906F-54B5-40F6-8FBD-E472E256D2CCQ33947008-02D53CA4-1066-4506-B64B-0F2550B59093Q34022578-3E83EF3E-A9E1-4DC9-88F5-2C79AF5361CEQ34177732-0444F889-B6D5-4482-A062-B7E46DA64874Q34273373-54A46FD5-D963-4AB6-B119-2A86788BFB34Q34374835-199BABE9-0B42-4103-9A33-E500BEDDD400Q34392963-877E453C-D456-4AA1-A068-58A7923F9520Q34473958-B9951D16-A983-4791-BDD3-6E5C7556AB32Q34478071-50FC5F39-88A6-42F6-BE91-A9A196FAB516Q34527469-FD05FAC8-FAC6-421C-9DE2-B3C1F84A79D6Q34540222-42FA4936-EAD8-4BDF-AB06-32005365F8CAQ34550046-40B9814C-DE57-4E68-A012-F4A6CF6E6FACQ34774808-CE726926-EA5F-406E-AB66-6DB7A4BB0904Q35010683-81D62104-86BE-4A95-9A4D-D8FF6E03CB1DQ35034268-68FCF3FA-D4B7-4C2C-8452-6D6449E50B1FQ35164477-59DD5616-D6E7-4F06-A7E4-FB961CAB71DEQ35651494-61BCB3BD-2AE8-42DB-96BF-0583ED1C39A2Q35685300-945936D7-39B8-4DC6-A19F-89B736F99F82Q35686970-731AAD0E-8FE1-4CB2-B63C-6A931899DDBAQ35894094-B9042C8E-754D-47BC-9FEA-0D0F9C8FE3BDQ35914292-A7A0FEBA-9C7B-45FB-9C72-478722417579Q36118373-D4E16C38-9D77-4B1D-AF10-5A353B455C0DQ36131738-DFD6E012-CE7E-4BE9-86C2-8949D08CEDE0Q36155396-3EE590BD-7214-4140-B1BA-B88D65C65D04
P2860
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Two distinct broadly neutraliz ...... plications for vaccine design.
@ast
Two distinct broadly neutraliz ...... plications for vaccine design.
@en
type
label
Two distinct broadly neutraliz ...... plications for vaccine design.
@ast
Two distinct broadly neutraliz ...... plications for vaccine design.
@en
prefLabel
Two distinct broadly neutraliz ...... plications for vaccine design.
@ast
Two distinct broadly neutraliz ...... plications for vaccine design.
@en
P2093
P2860
P50
P356
P1433
P1476
Two distinct broadly neutraliz ...... plications for vaccine design.
@en
P2093
Chun-Yen Tsao
Daniel M Kozink
Georgia D Tomaras
Hua-Xin Liao
John A Crump
Kwan-Ki Hwang
Mattia Bonsignori
Noel E Sam
Peter D Kwong
Robert J Parks
P2860
P304
P356
10.1128/JVI.07163-11
P407
P577
2012-02-01T00:00:00Z